Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
It is very uncertain whether sunitinib changes serious adverse events (Grade 3 or 4) compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with atezolizumab (targeted therapy versus immunotherapy) (moderate certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
Sunitinib may leads to lower serious adverse events (Grade 3 or 4) compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).